Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Pfizer

Status and phase: Completed; Phase 2

Conditions: Dyslipidemia

Treatments: Drug: CP-778,875

Study type: Interventional

Funder types: Industry

Identifiers

NCT00326326

A5561005

Details and patient eligibility

About

To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes

Sex: All

Ages: 30 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women
• Triglycerides between 150-500 mg/dL
• Fasting Plasma Glucose 140-240 mg/dL

Exclusion criteria

• Known cardiovascular, carotid, or peripheral vascular disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind